Company intelligence / Profile preview

BioClin Therapeutics

Ownership: Private
Development stage: Other

Overview

BioClin Therapeutics was a privately-held, clinical-stage biotechnology company developing vofatamab (B-701), a first-in-class human monoclonal antibody targeting FGFR3 for the treatment of metastatic and early stage bladder cancer. The lead program advanced through Phase 2 trials both as monotherapy and in combination with standard-of-care agents such as docetaxel and pembrolizumab. In late 2018, the company rebranded to Rainier Therapeutics ahead of planned pivotal studies.

Therapeutic areas: Oncology
Modalities: Monoclonal antibodyBiologic
Industry: Biotech

Drug pipeline

2 assets

2QR-complex

1 more asset in the full pipeline.

Request access →

Partnerships

No major pharma partnerships disclosed; investor syndicate included Sectoral Asset Management, Sofinnova Ventures, INKEF Capital.

Beyond the preview

Go deeper on BioClin Therapeutics.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on BioClin Therapeutics.

Explore the full profile